Guidelines for the Treatment of Urinary Incontinence and Overactive Bladder
Keywords:
urinary incontinence, overactive bladder, treatment, Muscarinic antagonists
Abstract
Urinary incontinence (Ul) is the involuntary leakage of urine, while overactive bladder (OABi is characterised by frequency, nocturia and urgency, with or without incontinence. This paper provides guidelines for the management of Ul and OAB, focusing on primary health care' Although Ul and oAB negatively impact on the patient's quality of life more severely than diabetes mellitus or rheumatoid arthritis, surveys have shown that more than 60% of persons with Ul never mention their problem to a doctor or nurse.Therefore, the primary care setting is ideal for screening, basic evaluation, and initial management of Ul and OAB. A focused history and examination will usually enable the practitioner to distinguish between the different types of incontinence, such as stress, urge (overactive bladder), mixed, overflow and continuous incontinence. It should include a vaginal examination and cough test in women, rectal examination in men, dipsticks urinalysis, and assessment of the post-void residual urine.A bladder diary filled in by the patient can be very useful. There may be reversible conditions causing or contributing to the patient's incontinence, such as urinary tract infection. ln certain cases referral to a specialist is required, e.g. patients with incontinence after previous surgery, or associated with pain or hematuria. However, many patients with symPtoms of OAB or Ul can be effectively treated at the primary care level. Management options include lifestyle modification (e.g. smoking cessation and weight loss), pelvic floor exercises, and pharmacotherapy. Overactive bladder can be treated with muscarinic antogonists such as tolterodine and orybutinin.
Issue
Section
Original Research
By submitting manuscripts to SAFP, authors of original articles are assigning copyright to the South African Academy of Family Physicians. Copyright of review articles are assigned to the Publisher, Medpharm Publications (Pty) Ltd, unless otherwise specified. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAFP for educational and research purposes without obtaining permission.